BIO-RAD Laboratories director Allison Schwartz exercised Options for 117 shares at $0 per share on 2026-09-01. The post-transaction figures give investors her reported ownership at 1,573 shares before a forfeiture, followed by 1,530 shares, alongside 75 derivative securities.
Key Highlights
- Allison Schwartz reported ownership of 1,573 shares after the option exercise.
- A separate forfeiture was priced at $380.96 per share.
- Schwartz reported 75 derivative securities after the transactions.
BIO-RAD LABORATORIES, INC. (NYSE: BIO) recorded director Allison Schwartz’s exercise of options for 117 shares at $0 per share on 1 September 2026. Her reported ownership after the exercise was 1,573 shares.
Schwartz Reports Share
and Derivative Holdings Schwartz’s activity also included derivative securities, with ownership of 75 after the transactions. A separate forfeiture on 1 September 2026 was priced at $380.96 per share. Her reported share ownership after that transaction was 1,530 shares. The disclosed activity includes the option exercises and the forfeiture.
FAQs
Q: What did Allison Schwartz do with BIO-RAD Laboratories shares?
A: Allison Schwartz exercised options for 117 BIO-RAD Laboratories shares at $0 per share on 1 September 2026. Her reported ownership after the exercise was 1,573 shares.
Q: How many BIO-RAD shares did Allison Schwartz own after the forfeiture?
A: Allison Schwartz reported ownership of 1,530 BIO-RAD Laboratories shares after the separate forfeiture. The filing states that 43 shares were forfeited at $380.96 per share on 1 September 2026.
Q: How many derivative securities did Allison Schwartz hold?
A: Allison Schwartz reported ownership of 75 BIO-RAD Laboratories derivative securities after the transactions. The filing states that she exercised options for a total of 117 derivative securities across two transactions at $0 per share.
Download Free Report – Explore 3 Stock Ideas & Industry Insights
Unlock 3 stock ideas and key industry insights in our free report. This information is general in nature and does not consider your personal objectives, financial situation, or needs. It is not financial advice.
All investments involve risk—consider independent advice before making any investment decisions.
View 3 Research Reports
Disclaimer:
Kalkine Equities LLC, with Delaware File Number 4697384, Foreign Qualification Registration in California File Number 202109211078, and Texas File Number 805521396, is authorized to provide general advice only. The information on https://kalkine.com/ does not take into account any of your investment objectives, financial situation or needs. You should consider the appropriateness of advice taking into account your own objectives, financial situation and needs and seek independent financial advice before making any financial decisions. The link to our Terms and Conditions and Privacy Policy has been provided for your reference. On the date of publishing the reports (mentioned on the website), employees and/or associates of Kalkine do not hold positions in any of the stocks covered on the website. These stocks can change any time and readers of the reports should not consider these stocks as advice or recommendations later.